N/A N=12 Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI
Hyperpigmentation
Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
N/A N=25 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation
Vitiligo
Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002
Phase 4 N=20 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants
Phase 4 N=89 The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
Glaucoma · Application Site Pigmentation Changes
Primary: The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and…
N/A N=30 Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
Phase 4 N=123 AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Acne Vulgaris
Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 4 N=100 Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
Nasolabial Folds
Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…
N/A N=115 PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
Benign Pigmented Lesions · Facial Wrinkles
Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
N/A N=100 Safety Study of Cosmetic Tissue Augmentation in People of Color
Wrinkles
Primary: Keloid Formation at Site of Injection — 0.0 percentage of participants
N/A N=39,374 Investigating Healthcare Disparities in Vitiligo
Vitiligo
Primary: Risk of Depression Within Patients With Vitiligo — 1412; 5395 Events
N/A N=124 Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
Skin Aging
Primary: Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores — 0.18; 0.30 Units on a scale — p=<0.001
N/A N=10 Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
Vitiligo · Dermatology/Skin - Other
Primary: Molecular Changes From NB-UVB Therapy
N/A N=27 Fractionated 1927nm Laser for Diffuse Pigmentation and Actinic Changes.
Skin Pigment
Primary: Change in Dyspigmentation Spots — 48.3; 46; 42.2; 42.5 Dyspigmentation Spots
N/A N=18 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
Melasma
Primary: Change From Baseline in Melasma Severity Rating Scale Score to Week 12 — 2.1; 2.1; -0.3; -0.8 score on a scale — p=0.041
N/A N=42 755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars
Benign Pigmented and Vascular Lesions and Scars
Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants
N/A N=32 A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal
Pigmented Skin Lesion of Suspected Benign Nature
Primary: Percentage of Participants With Change of Treated Lesions — 44; 44; 13 % of participants
N/A N=20 Laser Removal of Age (Sun) Spots on Hands
Solar Lentigines
Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001
Phase 2 N=19 Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
Melasma
Primary: Change in Melasma Area and Severity Index (MASI) Score — -11.4 units on a scale — p=0.006
Phase 3 N=50 Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Acne Vulgaris
Primary: Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire — 36 Participants
N/A N=88 Performance of Masimo MightySat Pulse Oximeter in Differing Levels of Skin Pigmentation
Healthy
Primary: SpO2 Accuracy of the MightySat Pulse Oximeter — 1.30 % of oxygen saturated hemoglobin
N/A N=50 A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
Solar Lentigines
Primary: Solar Lentigines Count — 25.7; 26.0; 8.0; 11.0 Number of solar lentigines
N/A N=24 Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
Poikiloderma of Civatte · Dyschromia · Pigmentation Disorders
Primary: Severity Assessment Score — -0.06; 0.2 score on a scale
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
N/A N=10 Post Market Clinical Follow Up Study to Collect Additional Data and Imaging
Pigmentation · Wrinkle
Primary: Correct Identification of Baseline Photographs vs. Photographs Taken 3 Months Post Last Treatment — 80 % of photos correctly identified
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions
Phase 4 N=21 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Investigator Global Assessment Scale for Severity of Facial Acne — 0; 0; 11; 9 Participants
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008